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A BST R AC T  
 
Aim: To compare the effect of administration of 2 different doses of platelet rich plasma (PRP) and a 
single dose of hyaluronic acid (HA) preparation on pain and daily life activities of knee osteoarthritis 
(KOA) patients. 
Method: In this nonrandomized comparative study, three groups of patients who received either a 
single dose of intraarticular (IA) PRP (PRP1 group), three doses of IA PRP (PRP3 group), or single 
dose IA HA (HA group) were included. Assessments were before treatment, and in the 3rd week and 
6th week after treatment (after the final injection). The pain-visual analog scale (VAS), Euro-Qol 
(EQ)-5D-3L, EQVAS, and the Western Ontario and McMaster Universities Osteoarthritis Index 
(WOMAC) were used. 
Results: In the 3rd week, there were statistically significant differences between the PRP1-HA groups 
in all parameters except EQ5; between PRP3-HA groups in all parameters except EQ5 and WOMAC 
stiffness; and between PRP3-PRP1 groups in all parameters except EQVAS, WOMAC pain and 
WOMAC stiffness. In the 6th week, there were statistically significant differences between the PRP1-
HA groups in all parameters except WOMAC stiffness; between PRP3-HA groups in all parameters; 
and between PRP3-PRP1 groups in all parameters except WOMAC pain. 
Conclusion: Intraarticular PRP injections (single or three doses) were found to be more beneficial in 
the short term in terms of pain and functional improvement than HA injection and administration of 
three consecutive doses of PRP may be more effective compared to single-dose PRP administration 
in KOA patients. 
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Osteoarthritis (OA) is the most commonly 
observed rheumatologic disease in the world 
resulting from primary progressive cartilage 
destruction [1]. Variations occurring as a result 
of OA are the main reason for situations leading 
to disability and are mostly observed in the knee 
joints [1-3]. Knee osteoarthritis (KOA) is a 
progressive joint disease frequently involving 
intra and periarticular structures characterized 
by joint cartilage lesions, synovitis, 
subchondral sclerosis and osteophytes. As a 
result of these, problems like pain, sensitivity, 
joint stiffness, swelling in the joint, movement 
limitation, joint deformity, muscle strength 
loss, reduced functional capacity and disrupted 
quality of life may be observed [1-3]. 
The targets of KOA treatment are to reduce 
pain, resolve joint stiffness, preserve and 
improve joint movement, preserve and increase 
muscle power, prevent trauma or protect 
against movements that may cause trauma and 
increase quality of life. Frequently used 
treatment methods for symptomatic KOA 
patients before surgery include systemic-effect 
anti-inflammatory medications, physiotherapy, 
topical anti-inflammatory gels and 
intraarticular injections. In spite of medical 
advances, there is no proven medication or 
surgical intervention to prevent or delay the 
development of KOA [3-6]. 
Intraarticular and periarticular injections have 
begun to be chosen for KOA treatment in recent 
years with the aim of improving symptoms and 
regulating daily life activities. Many studies 
have reported that hyaluronic acid (HA) has 
visco-induction properties and may increase the 
intraarticular viscosity and positively 
contribute to pain and mobilization. As a result, 
intraarticular HA injection is commonly used 
for KOA treatment [7].  Platelet rich plasma 
(PRP) is obtained by centrifuging full blood and 
is the plasma component containing higher 
concentrations of platelets than full blood [8]. 
As it contains many growth factors, the use of 
PRP injections for treatment of a variety of 
musculo-skeletal system diseases has come to 
the agenda. Growth factors, considered to affect 
the healing process, are locally injected into the 
lesion site with increasing effect on tendon and 
cartilage tissue regeneration and are stated to 
have potential use for treatment [9]. The 
minimal invasive treatment choice of 
intraarticular PRP injection is commonly used 
for treatment of clinically associated diseases 
like KOA. Some publications have proposed 
that PRP is a more reliable and effective 
treatment compared to other intraarticular joint 
injections [10, 11]. Additionally, though 
intraarticular HA and PRP administration are 
shown to resolve pain and improve joint 
functions in patients, there are contradictory 
publications about the efficacy for KOA 
patients [12].  
PRP and HA injections have increasing areas 
and frequency of use with every day and are 
chosen for musculoskeletal system pathologies 
with different indications. In spite of this 
frequent use, there is no treatment algorithm 
prepared based on evidence related to definite 
indications and administration frequency. 
Additionally, there are many different brands 
on the market, and PRP kits with different 
features and contents and HA preparations 
which causes further confusion. In our study we 
compared the effect of administration of 2 
different doses of PRP and a single dose of HA 
preparation on pain and daily life activities of 
KOA patients.   
 
Materials and Methods 
Study design 
This nonrandomized comparative study was 
carried out in the Bolu İzzet Baysal Physical 
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Medicine and Rehabilitation Training and 
Research Hospital, after Ethical Committee 
approval (Usak University Medical School 
Ethics Committee, decision number 31-5-13, 
dated 2018/04/25). The study protocol abided 
by the principles of the Helsinki Declaration. 
Participants in the research first read and then 
signed the consent form. 
Participants 
The study included patients attending the 
Physiotherapy and Rehabilitation Clinic from 
January 2019-January 2020 with diagnosis of 
KOA who received knee intraarticular PRP or 
HA treatment and agreed to complete the 
survey forms. 
Inclusion criteria for the study were age over 30 
years, gonarthrosis diagnosis according to 
American College of Rheumatology (ACR) 
criteria [3], and cases identified as stage 1-2-3 
according to radiological Kellgren-Lawrence 
classification [12]. 
Exclusion criteria for the study were presence 
of inflammatory rheumatologic disease, 
coagulation disorder, and immunosuppressive 
disease, diseases causing disruption to 
hemogram parameters, serious cardiovascular 
disease, previous operation in the knee region, 
varus and valgus deformity of the knee region, 
malignancy, infection, anticoagulant 
medication use, and use of anti-inflammatory 
medication in the last 1 week.  
A total of 278 patients were assessed for the 
study. The study included 210 patients abiding 
by the study criteria and providing consent with 
the patient information form (Figure 1). The 
study grouped patients according to the 
treatment they received; 70 patients with a 
single dose of intraarticular (IA) PRP (PRP1 
group), 70 patients with three doses of IA PRP 
(PRP3 group) and 70 patients with single dose 
IA HA (HA group). It was not possible to blind 
the patients due to the design of the study and 
nature of the treatment. The outcome 
assessment process was blinded. Patient 
assessment and statistical analysis of outcomes 
were performed by a clinician and biostatistics 
expert blind to the treatments and groups of 
patients.  
Interventions 
In our study, all injections performed by a 
single clinician in the injection clinic under 
sterile conditions. IA injection used a single-use 
10 mL 21 G green-tip injector with the lateral 
approach in the suprapatellar region. In our 
clinic, PRP was administered either as single 
dose or three doses with one-week interval; this 
approach was previously investigated in 
Görmeli et al.’s study [11]. 
The PRP1 group had one single IA PRP dose 
administered. The PRP amount was 3 mL. 
Before injection, and in the 3rd and 6th weeks 
after injection patients were assessed in terms 
of pain and functional status. 
The PRP3 group had three doses of IA PRP 
administered at one-week intervals. The 
amount of PRP administered in each session 
was 3 mL. Before injection, and in the 3rd and 
6th weeks after injection patients were assessed 
in terms of pain and functional status. 
The HA group had a single dose of IA HA 
injection administered. Before injection, and in 
the 3rd and 6th weeks after injection patients 
were assessed in terms of pain and functional 
status. 
All patients with PRP administration used a Dr 
PRP®  Kit with FDA approval and CE 
certification offered to the market by Cureacell 
Ltd. Co. The kit is offered to the market after 
gamma ray sterilization according to ISO 
13485 standards. For preparation of the Dr.PRP 
kit® , 3–4 ml of PRP with a concentration of 8–
10 times the average normal value and 2 cc of 
anti-coagulant were placed in a 20 cc syringe, 
then 18 cc of blood from patient was drawn. 
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The drawn blood was injected into the Dr. 
PRP®  kit through the upper injection port until 
the blood level reaches the 20-cc scale marked 
on the kit. After the first centrifugation at 3000 
rpm for 3-4 mins, the plasma layer and the red 
blood cell (RBC) layer were separated and then 
the separation position of the plasma and the 
RBC layer were identified and the height of the 
separated boundary to the indicated point was 
adjusted by pushing up or pulling down the 
adjusting knob located at the lower part of the 
Kit. In order to block the plasma and the RBC 
layer completely, the adjusting knob and the 
valve were fastened (clockwise). Finally, the 
adjusting knob was fastened again. The 
fastened PRP Kit was put into the centrifuge 
with counterbalance for the second 
centrifugation to enrich the concentrated 
platelets at 3250 rpm for 4-6 mins The PRP Kit 
was placed in upright position and the upper 
silicone lid on the Kit was opened. The PPP 
(platelet poor plasma) layer was slowly 
removed from the upper part using a 10-cc 
syringe with a needle, leaving 3 cc in the lower 
part (PRP). The PRP preparation procedure was 
performed by a trained nurse in our clinic. 
Patients with IA HA administered used the 
product with CE, ED and REP certification sold 
as ArtıAid®  Plus Intra-articular Injection 
commercial brand by Maxıgen Biotech Inc. 
High-purity HA has more than 1,500 kDa 
molecular weight with 45 mg HA (1.5%) 
included in 3 mL sodium hyaluronate solution 
prepared with buffered physiological saline in a 
single use sterile injector. 
During the treatment, patients were told they 
could use local ice compression and 
paracetamol (max 2 g/day) if required. 
Additionally, patients were given a home 
exercise program and recommended to return to 
normal daily activities 3 days after injection if 
tolerated.  
Instruments 
Assessments were before treatment, and in the 
3rd week and 6th week after treatment (after the 
final injection). Assessments used the pain-
visual analog scale (VAS), Euro-Qol (EQ)-5D-
3L, EQ VAS, and the Western Ontario and 
McMaster Universities Osteoarthritis Index 
(WOMAC). 
VAS is a commonly used method to determine 
the degree of pain. It comprises a line with 100 
mm length drawn on a horizontal or vertical 
axis. The distance from the lowest VAS value 
to the point indicated by the patient is measured 
in mm (0-100) and a numerical value is 
determined for the severity of pain felt by the 
patient [13].   
The 3-level version of EQ-5D (EQ-5D-3L) was 
developed by the European Quality of Life 
(Euroqol) Group in 1990. The EQ-5D-3L 
comprises 2 pages of the EQ-5D descriptive 
system and EQ visual analog scale (EQ-VAS). 
The EQ-5D is defined in terms of 5 
subdimensions (mobility, self-care, general 
activities, pain/discomfort and 
anxiety/depression) within a three-level 
structure of “no problem, moderate degree 
problems and advanced degree problems”. On 
scoring a value of 1 shows perfect health, while 
health status worsens as values reduce. The EQ-
VAS comprises a 100 mm line to assist in 
scoring the health status of a person with the 
best health status imaginable shown at 100 and 
the worst health status shown at 0 [14]. 
The WOMAC is a health status metric 
commonly used for knee and hip OA patients. 
It comprises three sections of pain, stiffness and 
physical function. It includes a total of 24 items. 
Points for items are given according to a Likert 
scale. Points from 0 to 4 are given on the Likert 
scale determining pain and degree of difficulty. 
Turkish validity and reliability studies have 
been performed [15]. 
                                              Dilekci et al / Exp Biomed Res. 2020; 3(4):262-276 




Socio-demographic (or other) variables such as 
age, gender and symptom duration (months) 
were recorded in all patients. 
Statistical methods 
The baseline characteristics were compared 
among groups by using the Kruskal-Wallis test 
or the Mann-Whitney U test for continuous 
variables and Pearson's chi-square test for 
categorical variables. Outcomes were analyzed 
with generalized linear mixed models with 
gamma regression. The models included group, 
time, some baseline characteristics (i.e. age, 
sex, OA grade), baseline value of outcome and 
group X time interaction as fixed effects. 
Follow-up and difference values are presented 
as generalized linear mixed models estimated 
mean (95% confidence interval). The 
sequential Bonferroni correction was used in 
the models. All statistical analyses were 
performed using SPSS. The level of statistical 
significance was set at 0.05. 
 
Results  
Of the total of 210 patients (70 x 3 groups) 
included within the scope of the study, the study 
was completed with 66 people in the PRP1 
group, 65 people in the PRP3 group and 68 
people in the HA group. In the PRP1 group, 3 
people did not continue to attend check-ups and 
5 people used NSAIDs; in the PRP3 group 6 
people used NSAIDs, 3 people ended 
participation after one or two injections, 1 
person developed history of trauma during 
follow-up and 2 people had arthroscopic 
surgery; and in the HA group 3 people did not 
continue to attend check-ups so the study was 
completed with a total of 176 patients. The flow 
diagram for the study is presented in Figure 1. 
The basic descriptive characteristics of patients 
are summarized in Table 1. 
The mean difference in pain VAS scores 
between the groups was identified to be 
statistically significant in the 3rd week. 
Estimated mean differences were -4.01 (95% 
CI, -6.86 to -1.16; p=0.006) between PRP1 and 
HA groups, -8.42 (95% CI, -11.87 to -4.97; 
p<0.001) between PRP3 and HA groups and -
4.41 (95% CI, -7.65 to -1.18; p=0.005) between 
PRP3 and PRP1 groups. The mean difference 
between pain VAS scores between the groups 
was identified to be statistically significant in 
the 6th week. The estimated mean differences 
were -6.31; 95% CI, -8.66 to -3.97; p<0.001, 
between PRP1 and HA groups, -9.86; 95% CI, 
-12.34 to -7.39; p<0.001 between PRP3 and 
HA groups and -3.55; 95% CI, -5.27 to -1.83; 
p<0.001) between PRP3 and PRP1 groups 
(Table 2, Figure 2). 
Mean differences between the EQ5 scores in 
the groups was only identified to be statistically 
significant between the PRP3 and PRP1 groups 
in the 3rd week. The estimated mean differences 
were -0.21; 95% CI, -0.06 to 0.019; p=0.303 
between PRP1 and HA groups, 0.03; 95% CI, -
0.10 to 0.078; p=0.132 between PRP3 and HA 
groups and 0.06; 95% CI, 0.01 to 0.10; p=0.016 
for PRP3 and PRP1 groups. In the 6th week, the 
estimated mean differences were 0.14; 95% CI, 
0.07 to 0.21; p<0.001 between PRP1 and HA 
groups, 0.24; 95% CI, 0.16 to 0.31; p<0.001 
between PRP3 and HA groups and 0.10; 95% 
CI, 0.02 to 0.18; p=0.006 for PRP3 and PRP1 
groups (Table 2, Figure 2). 
The mean differences between the EQ VAS 
scores in the groups was identified to be 
statistically significant between the PRP1-HA 
and PRP3-HA groups in the 3rd week. The 
estimated mean differences were 5.67; 95% CI, 
2.02 to 9.32; p=0.001 between PRP1 and HA 
groups, 5.86; 95% CI, 2.11 to 9.60; p=0.001 
between PRP3 and HA groups and 0.19; 95% 
CI, -3.15 to 3.52; p=0.913 for PRP3 and PRP1 
groups. Statistical significance was identified 
for the mean differences between groups for EQ  
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Did not continue allocated 
intervention n=4
Knee trauma n=1
Treated with intraarticular seroid 
injection=3






Did not continue allocated 
intervention n=5 
Knee trauma n=1
Treated with intraarticular seroid 
injection=1
Withdrew consent=3
Use of NSAIDs n=6
Knee trauma n=1
Withdrew consent (after first injection)=3





Did not continue allocated 
intervention n=2








Use of anticoagulants and antiplatelet drugs n=18
Inflammatory rheumatic disease n=9
Abnormal complete blood count n=13
Malignancy n=2
Underwent surgery n=6
Use of NSAIDs within the last weeks n=14
Not agree to participate in the study n=6
Table 1. Baseline characteristics of patients†. 






PRP1-HA PRP3-HA PRP3-PRP1 
Age, years 46.52 ±11.22 43.49 ± 12.06 49.18 ± 12.64 0.042 0.185 0.016 0.159 
Female sex 32 (55.2%) 29 (54.7%) 34 (52.3%) 0.943 NA NA NA 
Kellgren-Lawrence  
   Grade 1 
   Grade 2 

























Body mass index 
(kg/m2) 
26.95 ±3.64 26.68 ± 3.42 27.54 ± 3.32 0.230 NA NA NA 
Duration (Years) 4.38 ± 1.14 4.62 ± 1.37 4.86 ± 1.78 0.341 NA NA NA 
VAS Pain 72.50 ±9.56 80.66 ± 12.86 75.23 ± 10.13 0.001 0.216 0.007 <0.001 
EQ5 0.16 ± 0.22 0.09 ± 0.22 0.09 ± 0.19 0.068 NA NA NA 
EQ VAS 27.50 ±9.56 18.96 ± 12.38 24.77 ± 10.13 <0.001 0.063 0.004 0.037 
Womac Pain 11.29 ± 2.29 13.42 ± 3.10 12.45 ± 2.23 <0.001 0.002 0.023 <0.001 
Womac Stiffness 3.86 ± 1.07 4.91 ± 1.26 4.14 ± 1.00 <0.001 0.105 0.001 <0.001 
Womac Function 46.86 ± 7.43 52.70 ± 9.34 49.14 ± 7.47 <0.001 0.031 0.010 <0.001 
Womac Total 61.98 ± 10.33 71.15 ± 13.34 65.69 ± 9.60 <0.001 0.016 0.004 <0.001 
† The data are expressed as mean ± standard deviation or number (%). PRP: Platelet-Rich Plasma, VAS: Visual Analog Scale, EQ: European Quality 
of life, WOMAC: Western Ontario and Mc Master Universities Osteoarthritis index, NA: Not applicable. 
‡ The Kruskal-Wallis test was used for continuous variables; and Pearson's chi-square test was used for categorical variables between three groups 
(PRP1, PRP3, HA). § The Mann-Whitney U test was used for continuous variables between two groups. 
Figure 1. Flow diagram of the study population 
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VAS scores in the 6th week. The estimated 
mean differences were 8.21; 95% CI, 5.54 to 
10.87; p<0.001 between PRP1 and HA groups, 
14.89; 95% CI, 11.74 to 18.05; p<0.001 
between PRP3 and HA groups and 6.69; 95 % 
CI, 3.89 to 9.48; p<0.001 for PRP3 and PRP1 
groups (Table 2, Figure 2). 
There were statistically significant differences 
between the PRP1-HA and PRP3-HA groups in 
the 3rd week for the WOMAC-pain scores in the 
groups. The estimated mean differences were 
1.37; 95% CI, -2.06 to -0.68; p<0.001 between 
PRP1 and HA groups, -1.48; 95% CI, -2.24 to -
0.71; p<0.001 between PRP3 and HA groups 
and -0.11; 95% CI, -0.71 to 0.50; p=0.729 for 
PRP3 and PRP1 groups. Differences between 
the mean WOMAC-pain scores between the 
groups in the 6th week were identified to be 
statistically significant between the PRP1-HA 






















differences were -1.74; 95% CI, -2.31 to -1.17; 
p<0.001 between PRP1 and HA groups, -2.07; 
95% CI, -2.66 to -1.48; p<0.001 between PRP3 
and HA groups and -0.33; 95% CI, -0.671 to 
0.003; p=0.052 for PRP3 and PRP1 groups 
(Table 2, Figure 2). 
The mean differences between WOMAC-
stiffness scores in the groups in the 3rd week 
were identified to be statistically significant for 
the PRP1-HA groups. The estimated mean 
differences were 0.34; 95% CI, -0.63 to -0.06; 
p=0.013 between PRP1 and HA groups, -0.25; 
95% CI, -0.55 to 0.04; p=0.104 between PRP3 
and HA groups and 0.09; 95% CI, -0.16 to 0.34; 
p=0.462 for PRP3 and PRP1 groups. In the 6th 
week, mean differences between the WOMAC-
stiffness scores in the groups were identified to 
be statistically significant between the PRP3-
PRP1 and PRP3-HA groups. The estimated 























                                                                                                                    
      
Figure 2. Baseline values are mean (95%CI). Follow-
up values are generalized mixed models estimated 
mean (95%CI). The models included group, time, some 
baseline characteristics (i.e. age, sex, OA grade), 
baseline value of outcome and group X time interaction 
as fixed effects. VAS: Visual Analog Scale, EQ: 
European Quality of life, WOMAC: Western Ontario 
and Mc Master Universities Osteoarthritis index. 
Generalized linear mixed models adjusted (sequential 
Bonferroni) P values are presented. 
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0.03; p=0.099 between PRP1 and HA groups, 
0.43; 95% CI, -0.66 to -0.20; p<0.001 between 
PRP3 and HA groups and -0.27; 95% CI, -0.51 
to -0.04; p=0.019 for PRP3 and PRP1 groups 
(Table 2, Figure 2). 
There were statistically significant differences 
between the groups in the 3rd week for the 
WOMAC-function scores. The estimated mean 
differences were -4.10; 95% CI, -6.32 to -1.87; 
p<0.001 between PRP1 and HA groups, -6.54; 
95% CI, -8.92 to -4.15; p<0.001 between PRP3 
and HA groups and -2.44; 95% CI, -4.36 to –
0.52; p=0.013 for PRP3 and PRP1 groups. 
Differences between the mean WOMAC-
function scores between the groups in the 6th 
week were identified to be statistically 
significant. The estimated mean differences 
were -6.88; 95% CI, -9.07 to -4.69; p<0.001 
between PRP1 and HA groups, -8.94; 95% CI, 
-11.18 to -6.70; p<0.001 between PRP3 and 






















p=0.002 for PRP3 and PRP1 groups (Table 2, 
Figure 2). 
The mean difference between WOMAC-total 
scores in the groups in the 3rd week were 
identified to be statistically significant. The 
estimated mean differences were -5.74; 95% 
CI, -8.61 to -2.88; p<0.001 between PRP1 and 
HA groups, -8.73 95% CI, -11.82 to -5.63; 
p<0.001 between PRP3 and HA groups and -
2.98; 95% CI, -5.47 to -0.49; p=0.019 for PRP3 
and PRP1 groups.  
In the 6th week, mean differences between the 
WOMAC-total scores in the groups were 
identified to be statistically significant. The 
estimated mean differences were -9.04; 95% 
CI, -11.85 to -6.23; p<0.001 between PRP1 and 
HA groups, -11.73; 95% CI, -14.60 to -8.86; 
p<0.001 between PRP3 and HA groups and -
2.69; 95% CI, -4.31 to -1.08; p=0.001 for PRP3 
and PRP1 groups (Table 2, Figure 2). 
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The study found statistically significant 
differences between the PRP1-HA groups in all 
parameters except EQ5, between PRP3-HA 
groups in all parameters except EQ5 and 
WOMAC stiffness, and between PRP3-PRP1 
groups in all parameters except EQVAS, 
WOMAC pain and WOMAC stiffness in the 3rd 
week; and statistically significant differences 
between the PRP1-HA groups in all parameters 
except WOMAC stiffness; between PRP3-HA 
groups in all parameters; and between PRP3-
PRP1 groups in all parameters except WOMAC 
pain in the 6th week. 
The targets of treatment for KOA include 
controlling pain, minimizing physical 
limitations, increasing quality of life and if 
possible, stopping progression of pathological 
processes [3-6]. Treatment should be 
specifically organized according to each 
individual based on patient expectations, 
disease severity, activity level and presence of 
comorbid diseases [3-6]. The minimal invasive 
treatments of intraarticular HA and PRP 
administration are commonly used treatment 
alternatives. Though many studies have been 
published about both treatment methods, 
effects and efficacy are still controversial [8-
12]. 
In KOA treatment, just as with IA PRP 
injection, the use of autologous growth factors 
is increasing [16]. PRP is the most convenient 
agent to obtain when compared with products 
containing other autologous growth factors. 
PRP contains factors like platelet-derived 
insulin-like growth factor, fibroblast growth 
factor, platelet-derived growth factor, 
epidermal growth factor and venous endothelial 
growth factor. These factors obtained from PRP 
may change the inflammatory process and have 
been shown to assist in preserving and 
regenerating tissue structure [17,18]. Due to 
these features, PRP is used in many different 
areas, not just for joint pathologies [19]. PRP 
contributes to the repair processes in 
subchondral bone and cartilage in KOA [20]. It 
reduces the negative effects of knee pain and 
inflammatory response [21]. Many reviews 
have reported positive clinical effects of PRP 
injection. PRP was shown to reduce pain and 
improve osteoarthritis indices (WOMAC total 
score, WOMAC subscores and Lequesne score) 
in KOA patients [22-29]. 
PRP injection is observed to be effective in 
early symptomatic OA knees. Outcomes after 
treatment show a clear reduction in pain in the 
12th month compared to situation before 
treatment and continued improvement in knee 
functions [22]. A study of patients with 
moderate stage KOA administered a single 
injection of PRP and two and three doses of 
PRP at two-week intervals and analyzed results 
at the end of the 6th month. In conclusion, they 
showed that for improvement in functional 
status and pain, a minimum of two injections 
were required [30]. A study of late stage (stage 
IV) KOA patients with single dose PRP and 
single dose steroid injection identified that the 
daily life activities, pain and QoL scores were 
similar in the two groups in the 6th month, with 
a significant improvement compared to initially 
[31]. 
A meta-analysis included many studies 
researching the clinical effect of PRP and stated 
that PRP was effective for KOA treatment but 
there was no clear evidence about dose or 
frequency. In this study, Vilchez-Cavazos et al. 
assessed 6-month outcomes and stated that 
single dose PRP had similar levels of 
improvement in terms of pain to multiple PRP 
doses; however, multiple dose PRP groups had 
more significant improvement in terms of joint 
functions [32]. Patel et al. compared efficacy at 
the end of the 6th month for 1 and 2 doses of 
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PRP with single-dose saline injection and 
showed that PRP injections ensured better 
improvement compared to saline injections in 
terms of WOMAC scores; however, there was 
no difference between the two PRP injections 
[33]. Görmeli et al. showed that three doses of 
PRP injection provided significantly better 
improvement compared with a single injection 
for early OA (stage I, II, III) patients; however, 
in advanced OA patients (stage IV) there was 
no difference between the groups [11]. In our 
study, early and moderate stage KOA patients 
(stage I, II, III) had the short-term effects of 
PRP injection investigated and both PRP 
groups had independent improvement 
identified in terms of pain (VAS), quality of life 
scores (EQ-5D) and daily life activities 
(WOMAC). The group with 3 consecutive PRP 
injections were identified to have significant 
improvement in the 3rd and 6th weeks compared 
to the PRP1 group. 
Significant problems experienced with PRP 
administration may be listed as obtaining PRP 
solution amounts, platelet concentration in 
contents, use of tubes and kits with different 
features, homogenization of obtained PRP and 
user experience [34,35]. In our study, a PRP kit 
abiding by standardization as determined by the 
Turkish Ministry of Health and international 
standards and with safety certification was 
used. The PRP solutions for administration 
were prepared by an experienced health staff 
with clinical training and administered by a 
single clinician. 
Patients with HA injection, assessed in many 
studies for knee treatments, were not identified 
to have any difference compared to patients 
with single-dose PRP injection. Patients with 
multiple PRP doses were identified to have 
greater improvement than patients with one of 
the other two treatments administered [34, 36-
40]. 
In the literature, though studies comparing PRP 
and HA injections and meta-analyses have 
generally emphasized that IA PRP 
administration is more effective compared to 
HA administration in terms of pain and 
functional improvement [23, 27, 29, 41-43], a 
few meta-analyses have reported the opposite 
view [44, 45]. PRP injection was shown to be 
more effective in reducing symptoms in mild 
and moderate (stage I, II, III) KOA patients who 
do not respond to traditional treatment and in 
improving function and quality of life 
compared to HA injection and placebo in many 
studies in the literature [42, 46-49]. 
Görmeli et al. in a study of PRP and HA 
injections showed that there were significant 
degrees of improvement in early OA (stage I, 
II, III) patients in terms of pain and function 
improvement; however, there was no difference 
between the groups for advanced OA (stage IV) 
patients [34]. Zhang et al. compared pain, 
function and quality of life indices after PRP 
and HA injections and showed that patients in 
different stages of KOA did not show the same 
response to PRP or HA treatment [12]. Kon et 
al. investigated three homogeneous patient 
groups treated with PRP, low-molecular weight 
HA and high molecular weight HA and 
concluded that autologous PRP injections had 
longer duration of efficacy compared to HA 
injections and improved joint functions [47]. In 
our study, early and moderate stage (stage I, II, 
III) KOA patients had single dose and triple 
dose of PRP and high-molecular weight HA 
administered IA. There are standardization 
problems with PRP kits and the treatment 
performed with these kits and with HA 
preparations. Products offered for use may be 
obtained with different technological methods, 
have different molecular weights and doses, 
and have problems like being straight or cross-
linked causing different treatment outcomes 
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and complications to be encountered. In our 
study, all patients had PRP kit and HA 
preparations administered with the same brands 
and features. No infection or allergic reactions 
were encountered during follow-up. In the 3rd 
and 6th weeks after injections, scores indicating 
pain, quality of life and daily life activities were 
improved in all groups. This improvement was 
identified to be at more significant levels in the 
PRP groups compared to the HA group. When 
the PRP groups are compared, all scores in the 
PRP3 group were significantly better than the 
PRP1 group. In our study, we think the short-
term efficacy of PRP injections is due to 
symptomatic amelioration occurring with 
physiological variations effective on pain in the 
intra/periarticular region, rather than positive 
changes to the pathologic degeneration process 
in the joint structure or knee OA. However, the 
improvement after PRP treatment compared to 
HA treatment, more pronounced after three 
doses of PRP, leads to consideration that the 
regeneration process begins in the short term. In 
order to reveal regenerative changes after PRP 
administration, it is necessary to perform 
moderate and long-term follow-up with 
radiological and histopathological 
investigations needed to prove these changes. 
The nonrandomized design, the patient follow-
up duration being limited to 6 weeks, and not 
showing the presence of regeneration after the 
administered treatments with histopathologic 
and/or imaging methods may be listed as 
important limitations of our study. Also, the 
lack of recording the adherence to home 
exercise program is another limitation: patients 
who adhered to home exercise program might 
have been better improvements than those who 
did not adhere to it. 
Conclusions 
Intraarticular PRP injections (single or three 
doses) were found to be more beneficial in the 
short term in terms of pain and functional 
improvement than HA injection and 
administration of three consecutive doses of 
PRP may be more effective compared to single-
dose PRP administration in KOA patients  
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